Madrigal fatty liver drug clears safety hurdle in late-stage study

Madrigal Pharmaceuticals said on Monday that its experimental pill significantly reduced liver fat by just under half without any serious safety concerns – meeting the goals of a “real-life” Phase 3 clinical trial involving patients with fatty liver disease known as NASH.

With just under 1,000 patients treated for one year, the main objective of the study was to demonstrate that Madrigal’s NASH treatment, called resmetirom, could be administered chronically without causing potentially harmful side effects.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is that?

STAT+ is STAT’s premium subscription service for in-depth coverage and analysis of biotechnology, pharmaceuticals, policy and life sciences. Our award-winning team covers news from Wall Street, political developments in Washington, early scientific breakthroughs and clinical trial results, and healthcare disruptions in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerful team of journalists
  • Newsletters reserved for subscribers
  • Daily newsletters to inform you about the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our journalists and leading industry experts in live video chats
  • Exclusive industry events
  • Premium access to subscriber-only networking events nationwide
  • The best journalists in the industry
  • The most trusted, best-connected newsroom in healthcare
  • And much more
  • Exclusive interviews with industry leaders, profiles and premium tools, like our CRISPR Trackr.

Comments are closed.